GSK 2315698

Drug Profile

GSK 2315698

Alternative Names: 2315698; CPHPC - GlaxoSmithKline; GSK2315698; GSK2315698A

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pentraxin Therapeutics
  • Developer GlaxoSmithKline
  • Class Antidementias
  • Mechanism of Action Serum amyloid P component inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyloidosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Amyloidosis in United Kingdom (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Amyloidosis in United Kingdom (SC, Injection)
  • 10 Jul 2017 Phase-II clinical trials in Amyloidosis (Combination therapy) in United Kingdom (IV) (NCT03044353)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top